Archive · 23 Jul 2026
Cipla Q1FY27: Profit Drops 39% Despite Record India Sales
Cipla, a big Indian medicine company, recently shared its financial results for the first three months of the fiscal year 2027.
The company made less profit compared to the same time last year, with a big drop of 39.19%.
However, its sales in India were the highest ever, growing by 12%.
The company also launched new medicines in the US to grow in important health areas.
Despite these good things, the company's overall earnings before interest, taxes, depreciation, and amortization (EBITDA) fell, and its profit margins got smaller.
The company's stock price also went down a bit after these results were announced.
Cipla's Q1FY27 net profit declined by 39.19% year-on-year to Rs 789.05 crore.
Revenue from operations rose by 2.3% year-on-year to Rs 7119.28 crore.
EBITDA declined to Rs 1,192 crore, with a margin narrowing to 16.7% from 25.6%.
India business achieved its highest-ever quarterly revenue, growing 12% year-on-year.
Cipla launched new products like Nintedanib and Dapagliflozin in the US.
- Who
- Cipla, an Indian pharmaceutical company
- What
- Reported a 39.19% decline in net profit for Q1FY27
- When
- Q1FY27 (April-June 2026)
- Where
- Global operations with significant focus on India and North America
- Why
- Despite record sales in India and new product launches, overall financial performance declined.
Positive Growth Areas
Financial Decline
India Business Performance
Positive Growth Areas
Cipla's India business achieved its highest-ever quarterly revenue, growing 12% year-on-year.
Financial Decline
Overall, Cipla reported a 39.19% decline in net profit and a 34.3% drop in EBITDA.
Product Launches
Positive Growth Areas
Cipla launched new products like Nintedanib and Dapagliflozin to strengthen its presence in high-growth therapy areas.
Financial Decline
Despite new product launches, the company's EBITDA margin narrowed significantly to 16.7% from 25.6%.
- Net Profit
- Rs 789.05 crore (Q1FY27)
- Revenue from Operations
- Rs 7119.28 crore (Q1FY27)
- EBITDA
- Rs 1,192 crore (Q1FY27)
- EBITDA Margin
- 16.7% (Q1FY27)
- India Business Revenue Growth
- 12% year-on-year
- North America Revenue
- $162 million (Q1FY27)
- Albuterol Market Share
- 21% in the US Albuterol MDI market
- Share Price Change
- -3.34% following Q1FY27 results
